论文部分内容阅读
目的:分析氯雷他定预防急性上呼吸道感染诱发幼儿喘息性支气管炎的疗效,以供临床参考。方法:将我院2011年7月至2013年6月收治的急性上呼吸道感染患儿120例纳入本研究,根据随机原则分组。对照组患儿接受常规治疗,实验组患儿在此基础上辅以氯雷他定治疗。用药后观察7d,对比两组患儿在喘息性支气管炎发生率、不良反应发生率方面的差异性。结果:与对照组对比,我们发现实验组患儿喘息性支气管炎发生率明显较低,组间差异经统计学分析后认为有意义(p<0.05)。对比两组患儿用药期间不良反应发生率发现,组间差异统计学分析后认为无意义(p>0.05)。结论:氯雷他定可有效预防急性上呼吸道感染诱发的幼儿喘息性支气管炎,且不增加不良反应,今后可将其推广应用。
Objective: To analyze the curative effect of loratadine on the prevention of asthmatic bronchitis in children with acute upper respiratory tract infection for clinical reference. Methods: A total of 120 children with acute upper respiratory tract infection admitted to our hospital from July 2011 to June 2013 were included in this study and grouped according to random principles. Children in the control group received routine treatment, and children in the experimental group were supplemented with loratadine on this basis. After treatment for 7 days, the differences between the two groups in the incidence of asthmatic bronchitis and the incidence of adverse reactions were compared. Results: Compared with the control group, we found that the incidence of asthmatic bronchitis was significantly lower in the experimental group, and the difference between the groups was considered statistically significant (p <0.05). The incidence of adverse reactions was compared between the two groups of children medication, the difference between groups was considered statistically significant (p> 0.05). Conclusion: Loratadine can effectively prevent asthmatic bronchitis induced by acute upper respiratory tract infection without increasing adverse reactions, so it can be widely applied in the future.